Skip to main content
. 2024 Mar 12;115(5):1665–1679. doi: 10.1111/cas.16143

FIGURE 7.

FIGURE 7

Serum ITIH5 levels and diagnostic accuracy assessment. (A) Serum ITIH5 levels in CCA, HCC, Benign, CHB, and Healthy. (B) Serum ITIH5 levels in iCCA, pCCA, and dCCA. (C–G) The ROC analysis results for ITIH5, CA19‐9, and the ITIH5/CA19‐9 panel in discriminating CCA patients from those with HCC, Benign, CHB, Healthy and NCCA, respectively. (H–L) The ROC analysis results for ITIH5, CA19‐9, and the ITIH5/CA19‐9 panel in discriminating iCCA patients from those with HCC, Benign, CHB, Healthy, and NCCA, respectively. ***p < 0.001. ns, no statistical differences. Benign, benign hepatobiliary diseases; CHB, chronic hepatitis B; CCA, cholangiocarcinoma; dCCA, distal cholangiocarcinoma; Healthy, healthy individuals; HCC, hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma; pCCA, perihilar cholangiocarcinoma; NCCA, the total patients without CCA.